23andMe Investor Presentation Deck
Our Scale Enables Real-Time Research
Across Multiple Disease Areas Including
(numbers below represent the number of research participants with the condition indicated)
Example Phenotype
Asthma
Type 1/ Type 2 diabetes
Irritable Bowel Syndrome
Osteoarthritis
Solid Tumors
Basal Cell
Squamous Cell
Melanoma
Breast
Colorectal
Thyroid
Hematologic Cancers
NHL
Leukemia
Retinal Diseases
AMD
Glaucoma
Rare Diseases
Sarcoidosis
Idiopathic Pulmonary Fibrosis
Number of Cases¹
1.2M
40K / 413k
742k
857k
> 1M
412k
222k
127k
119k
25k
27k
18k
14k
106k
193k
8.9k
5k
¹ As of December, 2022. 2 MedRXiv Sept. 7, 2020 (10.1101/2020.09.04.20188318). 3 Nature Genetics, 53, pages 801-808 (2021)
> 1.4M
COVID-19 study participants
COVID-19 Research
March 16 2020
April 6 2020
June 8 2020
Sept. 7 2020
750k
Consumers participated
in the COVID-19 study
in the first 90 days
April 22 2021
Kicked Off Study
Launched Study
Preliminary Findings
Posted Preprint Findings²
Published in Journal³
Re-contactable Customers
Participate in Health Research
29View entire presentation